SpringWorks Therapeutics Announces Closing Of Initial Public Offering and Exercise in Full of the Underwriter’s Option to Purchase Additional Shares

    NEXT STORY
    iBio’s Collaboration with South Africa’s AzarGen Biotechnologies Advances to Next Stage
    PREV STORY
    Translate Bio Announces Proposed Public Offering of Common Stock
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    TRIO Enrolls First Patient Into PHASE III NATALEE Clinical Trial

    Timely Enrollment Signifies Milestone in TRIOEDMONTON, Alberta, Jan. 14, 2019 (GLOBE NEWSWIRE) -- Translational ...

    author_avatar
    NASDAQ Market News

    Helix Biopharma Corp. Closes First Tranche of Private Placement

    RICHMOND HILL, Ontario, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX, FSE: ...

    author_avatar
    NASDAQ Market News

    Acer Therapeutics Reports Positive Results From Pivotal Clinical Trial of EDSIVO™ (celiprolol) for Treatment of Vascular Ehlers-Danlos Syndrome

    - Company intends to file NDA for EDSIVO™ in first half of 2018 - ...

    author_avatar
    NASDAQ Market News